VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
TELA
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
TELATELA Bio, Inc.
$0.74$33M
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders
HomeStocksTELABalance Sheet

TELA Bio, Inc. (TELA) Balance Sheet

9Y historyFree accessUpdated daily

The company's financial position has weakened significantly, with total debt of $55.9M now exceeding total assets of $69.9M as of 2026Q1.

TELA Balance Sheet

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18Dec'17
Total Current Assets64.3M75.58M78.07M71.73M62.45M59.05M83.22M64.33M23.25M14.35M
Cash & Short-Term Investments39.54M50.84M52.67M46.73M42.02M43.93M74.39M54.59M17.28M11.35M
Cash Only39.54M50.84M52.67M46.73M42.02M43.93M74.39M45.3M17.28M11.35M
Short-Term Investments00000009.29M00
Accounts Receivable9.71M10.35M10.1M9.74M6.62M4.23M2.68M2.84M1.3M757K
Days Sales Outstanding51.6847.0553.1960.858.3552.4553.7767.0257.2665.09
Inventory12.21M11.02M12.78M13.16M11.79M7.66M3.91M4.6M4.35M1.81M
Days Inventory Outstanding159.15155.04204.5261.93299.44262.46204.34272.12297.64386.73
Other Current Assets2.83M3.37M2.52M2.1M2.02M00000
Total Non-Current Assets5.59M5.84M9.25M6.32M5.41M3.49M3.23M3.59M3.97M1.19M
Property, Plant & Equipment3.6M3.73M4.08M3.94M2.91M1.19M626K677K758K1.16M
Fixed Asset Turnover21.72x21.53x16.99x14.84x14.24x24.84x29.09x22.82x10.92x3.66x
Goodwill0000000000
Intangible Assets1.26M1.36M1.74M2.12M2.5M2.3M2.61M2.91M3.21M0
Long-Term Investments1.9M250K2.54M265K0000024K
Other Non-Current Assets726K500K00000000
Total Assets69.89M81.42M87.33M78.05M67.86M62.54M86.46M67.92M27.23M15.53M
Asset Turnover1.15x0.99x0.79x0.75x0.61x0.47x0.21x0.23x0.30x0.27x
Asset Growth %12.05%-6.77%11.89%15.02%8.49%-27.66%27.29%149.47%75.3%-
Total Current Liabilities17.83M17.98M15.6M16.97M12.4M10.57M6.61M6.71M9.56M6.15M
Accounts Payable3.89M2.31M2.15M1.67M1.53M2.41M652K3.17M3.42M1.51M
Days Payables Outstanding35.5732.534.3533.1738.9582.7334.1187.47234.18321.11
Short-Term Debt00545K565K340K0000905K
Deferred Revenue (Current)0000000001.59M
Other Current Liabilities13.94M15.67M5.56M5.52M4.11M3.15M2.24M1.19M985K1.94M
Current Ratio3.61x4.20x5.01x4.23x5.03x5.58x12.60x9.58x2.43x2.33x
Quick Ratio2.92x3.59x4.19x3.45x4.08x4.86x12.01x8.90x1.98x2.04x
Cash Conversion Cycle175.26169.59223.33289.56318.83232.18224151.67120.72130.72
Total Non-Current Liabilities57.26M57.13M43.27M42.2M41.15M31.87M30.83M30.25M155.53M117.56M
Long-Term Debt55.87M55.65M41.12M40.52M39.92M31.49M30.83M30.24M29.73M3.61M
Capital Lease Obligations001.39M1.69M1.2M00000
Deferred Tax Liabilities00756K0000000
Other Non-Current Liabilities1.39M1.48M0031K380K04K125.8M113.94M
Total Liabilities75.09M75.11M58.87M59.17M53.55M42.45M37.43M36.96M165.09M123.7M
Total Debt55.87M55.65M43.06M42.77M41.46M31.49M30.83M30.24M29.73M4.51M
Net Debt16.32M4.81M-9.61M-3.96M-563K-12.44M-43.57M-15.06M12.46M-6.83M
Debt / Equity-10.74x8.82x1.51x2.26x2.90x1.57x0.63x0.98x--
Debt / EBITDA-1.68x---------
Net Debt / EBITDA-0.49x---------
Interest Coverage-16.87x-6.44x-6.18x-7.93x-9.93x-8.25x-7.08x-5.21x-10.70x-3.68x
Total Equity-5.2M6.31M28.46M18.88M14.3M20.1M49.03M30.96M-137.86M-108.17M
Equity Growth %138.31%-77.82%50.72%31.99%-28.82%-59.01%58.34%122.46%-27.45%-
Book Value per Share-0.090.131.000.830.881.393.792.71-21.25-16.67
Total Shareholders' Equity-5.2M6.31M28.46M18.88M14.3M20.1M49.03M30.96M-137.86M-108.17M
Common Stock45K44K39K24K19K15K14K11K07K
Retained Earnings-409.83M-397.56M-358.73M-320.89M-274.23M-229.93M-196.65M-167.86M-137.86M-108.17M
Treasury Stock0000000000
Accumulated OCI85K91K90K91K150K-52K-71K-19K-3.24M-2.79M
Minority Interest0000000000

Key Metrics

Growth RegimeDecelerating
ProfitabilityNegative
Balance SheetVulnerable
Cash FlowBurning
Top Statement Risk

Liquidity and capital exhaustion

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q1)

Diminishing Cash Runway Pressures Operations

According to recent SEC filings, TELA's cash position has contracted to $39.5M as of 2026Q1, down from $50.8M in 2025Q4, which highlights a tightening liquidity buffer that may necessitate external financing if the current burn rate persists throughout the remainder of the fiscal year.

The rapid depletion of cash reserves relative to the company's persistent operating losses suggests that management is facing a narrowing window to achieve self-sustaining cash flow. Investors should monitor the current ratio, which remains adequate at 3.61, but the underlying cash burn indicates that liquidity could become a critical constraint on operational flexibility in the near term.

Leverage Profile Reflects Financial Strain

As reported in financial statements, TELA's total debt has risen to $55.9M in 2026Q1, creating a precarious capital structure where debt levels now exceed total assets, a trend that warrants further investigation into the company's long-term ability to service these obligations without further equity dilution.

The reliance on debt to fund ongoing commercial expansion in the face of negative equity suggests a high-risk financing strategy. This leverage profile implies that the company's cost of capital may increase significantly, potentially limiting its ability to invest in the R&D necessary to maintain its competitive position in the hernia repair market.

Erosion of Shareholder Equity Base

Based on TELA's reported figures, the company's equity has deteriorated into a negative $5.2M position as of 2026Q1, driven by the relentless accumulation of retained losses that now total $409.8M, signaling a significant impairment of the capital base available to support future growth initiatives.

The transition to negative equity reflects the cumulative impact of sustained operating losses and the high cost of market penetration. This trend suggests that the company is effectively operating on borrowed capital, which may limit management's strategic options and increase the likelihood of dilutive capital raises to restore the balance sheet.

Balance Sheet Quality Continues Weakening

As indicated by the quarterly balance sheet data, TELA's financial position has trended toward a more vulnerable state, with total assets declining to $69.9M while liabilities remain elevated at $75.1M, suggesting that the business model is struggling to generate the internal capital required for long-term stability.

The consistent decline in asset quality and the widening gap between liabilities and assets indicate that the company's growth trajectory is not currently supported by a strengthening financial foundation. This trajectory appears to confirm that the current commercial strategy is capital-intensive and may be reaching a point of diminishing returns.

TELA — Frequently Asked Questions

Quick answers to the most common questions about buying TELA stock.

What are the total assets of TELA Bio, Inc. (TELA)?

As of 2025, TELA Bio, Inc. (TELA) had total assets of $81.4M including $75.6M in current assets.

How much debt does TELA Bio, Inc. (TELA) have?

TELA Bio, Inc. (TELA) carries total debt of $55.7M, offset by $50.8M in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.

What is the book value or shareholders' equity of TELA Bio, Inc.?

TELA Bio, Inc. (TELA) has total shareholders' equity (book value) of $6.3M ($0.13 book value per share). Book value represents the net worth of the company belonging to common stock holders.

What is TELA Bio, Inc.'s current ratio and liquidity?

TELA Bio, Inc. (TELA) reported a current ratio of 4.20x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.